Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operations

Reuters11-08

Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operations

Overview

Exicure reports Q3 net loss of $2.4 mln, up from $1.1 mln last year
Company's cash position falls to $4.4 mln, as of September 30, 2025, from $12.5 mln at year-end 2024
Co believes that its existing cash and cash equivalents is not sufficient to continue to fund operations
Increased R&D and G&A expenses due to GPCR USA acquisition

Outlook

Company needs substantial additional financing to continue operations

Result Drivers

R&D EXPENSES - Increase in R&D expenses due to acquisition of GPCR USA
G&A EXPENSES - Slight rise in G&A expenses attributed to GPCR USA acquisition

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income Before Tax		-$2.44 mln
Q3 Net Income		-$2.44 mln
Q3 Operating Expenses		$2.39 mln
Q3 Operating Income		-$2.39 mln

Press Release: ID:nGNX94GhK9

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581831358?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-08 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581831358","market":"nz","top_or_hot":-1,"title":"Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operations</title></head><body><p><span>Overview</span></p><ul><li><p>Exicure reports Q3 net loss of $2.4 mln, up from $1.1 mln last year</p></li><li><p>Company's cash position falls to $4.4 mln, as of September 30, 2025, from $12.5 mln at year-end 2024</p></li><li><p> Co believes that its existing cash and cash equivalents is not sufficient to continue to fund operations</p></li><li><p>Increased R&amp;D and G&amp;A expenses due to GPCR USA acquisition</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company needs substantial additional financing to continue operations</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Increase in R&amp;D expenses due to acquisition of GPCR USA</p></li><li><p>G&amp;A EXPENSES - Slight rise in G&amp;A expenses attributed to GPCR USA acquisition</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income Before Tax</p></td><td></td><td><p>-$2.44 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$2.44 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$2.39 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$2.39 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX94GhK9</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-08 05:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operations</title></head><body><p><span>Overview</span></p><ul><li><p>Exicure reports Q3 net loss of $2.4 mln, up from $1.1 mln last year</p></li><li><p>Company's cash position falls to $4.4 mln, as of September 30, 2025, from $12.5 mln at year-end 2024</p></li><li><p> Co believes that its existing cash and cash equivalents is not sufficient to continue to fund operations</p></li><li><p>Increased R&amp;D and G&amp;A expenses due to GPCR USA acquisition</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company needs substantial additional financing to continue operations</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Increase in R&amp;D expenses due to acquisition of GPCR USA</p></li><li><p>G&amp;A EXPENSES - Slight rise in G&amp;A expenses attributed to GPCR USA acquisition</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income Before Tax</p></td><td></td><td><p>-$2.44 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$2.44 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$2.39 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$2.39 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX94GhK9</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL1N3WJ166:1","article_id":"2581831358","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581831358","pubTimestamp":1762549868,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operationsOverviewExicure reports Q3 net loss of $2.4 mln, up from $1.1 mln last yearCompany's cash p","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XCUR":"Exicure, Inc."},"translate_title":"生物技术公司Exicure第三季度净亏损扩大，现有现金不足以继续为运营提供资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XCUR":0.9},"content_text":"Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operationsOverviewExicure reports Q3 net loss of $2.4 mln, up from $1.1 mln last yearCompany's cash position falls to $4.4 mln, as of September 30, 2025, from $12.5 mln at year-end 2024 Co believes that its existing cash and cash equivalents is not sufficient to continue to fund operationsIncreased R&D and G&A expenses due to GPCR USA acquisitionOutlookCompany needs substantial additional financing to continue operationsResult DriversR&D EXPENSES - Increase in R&D expenses due to acquisition of GPCR USAG&A EXPENSES - Slight rise in G&A expenses attributed to GPCR USA acquisitionKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income Before Tax-$2.44 mlnQ3 Net Income-$2.44 mlnQ3 Operating Expenses$2.39 mlnQ3 Operating Income-$2.39 mlnPress Release: ID:nGNX94GhK9For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581831358","isCrawlerRequest":true}